Propranolol Drug Market Report 2026

The propranolol drug market size has grown strongly in recent years. It will grow from $1.1 billion in 2025 to $1.15 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to high prevalence of hypertension, widespread epilepsy treatment, low-cost availability, hospital-based prescribing, inclusion in national formularies.

The propranolol drug market size is expected to see strong growth in the next few years. It will grow to $1.41 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, rising mental health disorders, demand for cost-effective therapies, expansion of generic drug markets, increased outpatient care. Major trends in the forecast period include sustained demand in cardiovascular disorders, increasing use in anxiety and migraine, expansion of generic propranolol, growth of extended-release formulations, inclusion in essential medicines programs.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the propranolol drug market in the coming years. Cardiovascular diseases (CVDs) include a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. Their increase is largely linked to unhealthy dietary habits, including excessive consumption of processed foods and fats, which elevate cholesterol levels and heighten heart disease risk. Propranolol helps manage cardiovascular diseases by regulating heart rate and lowering blood pressure, making it effective for patients with hypertension and arrhythmias. It improves heart function and reduces the risk of heart attacks and strokes, supporting overall cardiovascular health. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that 919,032 people in the U.S. died from cardiovascular disease in 2023, accounting for roughly one in three deaths nationwide. Therefore, the increasing prevalence of cardiovascular diseases is boosting the propranolol drug market.

Major companies operating in the propranolol drug market are focusing on developing advanced products, such as extended-release propranolol formulations, to improve patient adherence and overall therapeutic outcomes. Extended-release formulations are designed to release the drug gradually, providing sustained therapeutic effects and reducing the need for frequent dosing, thereby enhancing patient compliance and treatment effectiveness. For example, in August 2023, Lupin Pharma Canada Ltd., a Canada-based pharmaceutical company, launched Propranolol long-acting capsules to address the discontinuation of Inderal long-acting (LA). Available in 60 mg, 80 mg, 120 mg, and 160 mg strengths, the new formulation offers consistent symptom relief, improves adherence, and enhances overall treatment outcomes and healthcare access for Canadian patients.

In December 2024, Exicure Inc., a US-based biotechnology company, partnered with GPCR Therapeutics Inc. Through this collaboration, Exicure aims to strengthen its position as a clinical-stage biotech company by acquiring key technical personnel and securing GPCR Therapeutics’ proprietary CXCR4 inhibitor technology, advancing its drug development efforts in immuno-oncology, fibrosis, and obesity treatments. GPCR Therapeutics Inc. is a South Korea-based biopharmaceutical company that manufactures propranolol.

Major companies operating in the propranolol drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Fresenius Kabi AG, Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Ipca Laboratories Limited, Mankind Pharma Ltd., Lannett Company Inc., Jubilant Pharma Holdings Inc., Actiza Pharmaceutical Private Limited, Mylan Laboratories Inc., Neurocon Inc., Neuracle Lifesciences Pvt. Ltd., Yabang Pharmaceutical Group Co. Ltd.

North America was the largest region in the propranolol drug market in 2025. The regions covered in the propranolol drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the propranolol drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the propranolol market by increasing API procurement costs, particularly in regions that depend on imports from Asia. These impacts have been reflected in higher input expenses for generic manufacturers and tighter cost controls across production operations. Tariff related supply chain disruptions have also affected hospital procurement timelines and inventory planning. This has influenced pricing negotiations and sourcing strategies for cardiovascular drugs. However, trade barriers have supported domestic generic manufacturing, expanded local production capacity, and strengthened regional pharmaceutical production capabilities over the long term.

The propranolol drug market research report is one of a series of new reports that provides propranolol drug market statistics, including propranolol drug industry global market size, regional shares, competitors with a propranolol drug market share, detailed propranolol drug market segments, market trends and opportunities, and any further data you may need to thrive in the propranolol drug industry. This propranolol drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Propranolol is a non-selective beta-blocker that reduces heart rate, blood pressure, cardiac workload, and is also used for anxiety management and migraine prevention. It works by blocking the effects of adrenaline on the heart and blood vessels, thereby lowering heart rate and blood pressure. Propranolol is frequently prescribed to manage anxiety symptoms, particularly performance-related anxiety.

The main types of propranolol dosage forms include tablets, injectable solutions, extended-release capsules, and oral solutions. Propranolol tablets are solid oral medications containing propranolol hydrochloride, formulated for rapid absorption to treat conditions such as high blood pressure, arrhythmias, and anxiety, with dosing typically administered multiple times per day. They are used for various indications, including hypertension, angina pectoris, migraine prevention, post-traumatic stress disorder (PTSD), essential tremors, and anxiety disorders. The end users include hospitals, clinics, home healthcare settings, nursing homes, and pharmaceutical companies.

The propranolol drug market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.